Medinotec Inc (MDNC) Fair Value & Analysis
Healthcare · US · Market cap $58.8M
Medinotec Inc
MDNC · US
Fair value as of: Jul 19, 2026
From 24 valuation models · updated 22 days ago
Fair value updated Jul 19, 2026, revised from $1.46 to $1.28 (−12.3%) since Jun 24, 2026.
A solid business, but screening 74% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case ($1.63). The favourable scenario is already priced in.
- Solid but not exceptional quality (64/100) and above fair value, neither a clear bargain nor a standout compounder.
Price vs Fair Value (3 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 19, 2026.
How to read this chart
36‑month range $5.00 – $5.00 · fair‑value band $0.9300 – $1.63 · the $5.00 price screens above the $1.28 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 19, 2026.
Analysis
Medinotec Inc (MDNC) currently trades at $5.00, while our model-based Fair Value estimate is $1.28, implying the stock looks roughly 74.4% overvalued today. The Quality Score stands at 64/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Medinotec Inc generated revenue of $9.7M at a net margin of 8.2%. Revenue declined 48.3% year over year. It earns a return on equity of 15.9%. Net debt stands at $1.5M. Fundamentals as of Jul 19, 2026
Our scenario range runs from $0.9300 (bear case) to $1.63 (bull case); at $5.00, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades near its 52-week high, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -22% fair-value upside, at -74%, MDNC screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 24 models by family
Widest divergence: Growth Earnings ($3.14) versus Asset-Based ($0.3300). Highest evidence: Growth DCF (80).
Notify me when MDNC reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 19, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 67 · Market factors (momentum, volatility) 56
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Medinotec Inc. engages in the research and development, production, and sale of medical devices used in cardiology and airway-related procedures in South Africa, the United States, and internationally.
Full company description
Medinotec Inc. engages in the research and development, production, and sale of medical devices used in cardiology and airway-related procedures in South Africa, the United States, and internationally. The company offers semi-compliant percutaneous transluminal coronary angioplasty balloon catheters, suction dissectors, aortic perfusion and dilation catheters, chronic total occlusion catheters, and silicone tracheal stents; and distributes a range of cardiology and renal dialysis products. It serves hospitals, clinics, third-party healthcare providers, distributors, and other institutions, including governmental healthcare programs and group purchasing organizations. The company sells its products through the network of distributors and direct sales force. Medinotec Inc. was incorporated in 2021 and is headquartered in Johannesburg, South Africa.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2023 – FY2026 · reported fiscal years
Medinotec Inc reported revenue of $9.7M in FY2026 versus $1,000K in FY2023, a compound +113.5%/yr. Reported net income was $795K in FY2026.
MDNC screens 74% overvalued. Compare with Abbott Laboratories, →
Peer Group
Medical Devices · 352 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Devices median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jul 19, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | $100.68 | $74.79 | -26% |
| Stryker Corporation SYK | $316.44 | $186.28 | -41% |
| Medtronic plc MDT | $83.56 | $65.57 | -22% |
| Boston Scientific Corporation BSX | $43.04 | $38.44 | -11% |
| Edwards Lifesciences Corporation EW | $85.73 | $41.02 | -52% |
| Siemens Healthineers AG SHL | €34.59 | €33.87 | -2% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥149.43 | ¥147.63 | -1% |
| Shanghai United Imaging Healthcare Co 688271 | ¥109.00 | ¥43.60 | -60% |
| Demant A/S DEMANT | kr 276.60 | kr 161.17 | -42% |
| Getinge AB GETIB | kr 206.80 | kr 192.14 | -7% |
Compare Medinotec Inc with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Medinotec Inc (MDNC) overvalued or undervalued?
What is the fair value of MDNC?
What is the quality score of MDNC?
What is the revenue of Medinotec Inc (MDNC)?
What is the net profit margin of MDNC?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Medinotec Inc and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.